KRAS and metastatic malignant neoplasm in the lymph nodes: Like KRAS, it is noted that CTLA-4 expression was also higher in patients with lymph node metastasis, advanced pathological stages (72.7% vs. 50.0%), and MSI-stable cancer (68.4% vs. 25.0%).